Dr. Keedy on Regorafenib for the Treatment of GIST

Vicki Keedy, MD
Published: Tuesday, Nov 12, 2013

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the use of regorafenib for the treatment of patients with GIST.

Once patients progressed through imatinib and sunitinib, they had no FDA-approved options to treat their GIST. Many of these patients were treated off-label and by community doctors, rather than seek treatment on a clinical trial at an academic center.

Regorafenib provides an effective third-line drug, but Keedy says patients still are not coming onto clinical trials.

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the use of regorafenib for the treatment of patients with GIST.

Once patients progressed through imatinib and sunitinib, they had no FDA-approved options to treat their GIST. Many of these patients were treated off-label and by community doctors, rather than seek treatment on a clinical trial at an academic center.

Regorafenib provides an effective third-line drug, but Keedy says patients still are not coming onto clinical trials.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x